With our transformative technologies for antibody discovery and bioconjugation, we have established a rich pipeline of proprietary ADCs. Under various licensing and partnering agreements, we are collaborating with a number of partners to provide access to our unique research & development capabilities going from target to antibody to ADC.
Current ADC and mAb developments
Leveraging innovative technologies to transform targeted oncology
Unique high-throughput screening for function and internalization
Proprietary ADC technology with bioorthogonal click-chemistry
Proprietary genetic code expansion technology
Your partner from target to antibody to ADC
Our unique antibody screening platform and proprietary ADC technology enable us to create highly innovative targeted biotherapeutics.VERAXA has a proprietary pipeline and has also partnered with pharmaceutical and biotechnological companies to accelerate the development of superior ADCs and functional mAbs.We are open to strategic partnership that support our core strategy and increase the value of a growing drug pipeline.
If you are interested in partnering with us
We are your partner from target to antibody to ADC. Our unique antibody screening platform and proprietary ADC technology enable us to help you create the best targeted biotherapeutics for your application.
With partnership models tailored to your needs, we can join you at any step of your development journey, whether you are starting out with a target or are looking for a bioconjugation partner.